Compare ENTX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | CHMI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 83.3M |
| IPO Year | 2018 | 2013 |
| Metric | ENTX | CHMI |
|---|---|---|
| Price | $1.58 | $2.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $2.75 |
| AVG Volume (30 Days) | ★ 305.3K | 213.6K |
| Earning Date | 11-14-2025 | 03-05-2026 |
| Dividend Yield | N/A | ★ 14.87% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $124,000.00 | ★ $40,202,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.73 |
| P/E Ratio | ★ N/A | $143.57 |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.45 | $2.17 |
| 52 Week High | $3.22 | $3.68 |
| Indicator | ENTX | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 59.35 |
| Support Level | $1.55 | $2.65 |
| Resistance Level | $1.72 | $2.77 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 24.19 | 88.14 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.